Liraglutide Cost in Tennessee 2026: Prices, Insurance, Medicaid, and Compounding

What Does Liraglutide Actually Cost at Tennessee Pharmacies in 2026?

Brand liraglutide carries a manufacturer list price near $1,349 per month in 2026, but most Tennessee patients pay between $600 and $900 per month in cash after pharmacy-level discounts. The gap between list price and street price exists because large pharmacy benefit managers negotiate rebates that rarely reach cash-pay patients directly.

Saxenda (liraglutide 3 mg for obesity) and Victoza (liraglutide 1.8 mg for type 2 diabetes) are the two branded formulations approved by the FDA [1]. Neither has a true small-molecule generic; no FDA-approved generic liraglutide existed in the U.S. as of the first half of 2026 [2]. Biosimilar GLP-1 receptor agonists remain in development pipelines, but none had cleared the FDA's 351(k) pathway for liraglutide specifically by mid-2026.

At major Tennessee chains, including CVS, Walgreens, and Kroger Pharmacy, the 30-day cash price for Saxenda (3 pens, 18 mg/3 mL each) averages around $900 with a GoodRx-style coupon applied. Without any coupon, the same supply can ring up at the full list price. A 2023 analysis published in JAMA Health Forum found that list-to-net price gaps for GLP-1 receptor agonists exceeded 45% on average, meaning the rebate system primarily benefits insurers and PBMs rather than uninsured patients [3].

Patients with commercial insurance who clear a prior authorization (PA) may pay a $25 to $99 monthly copay depending on their formulary tier. Novo Nordisk's savings program can bring the out-of-pocket cost to $25 per month for eligible commercially insured patients, though it cannot be combined with federal insurance programs like Medicare or Medicaid [4].

SCALE Obesity (N=3,731), published in the New England Journal of Medicine in 2015, established that liraglutide 3 mg produced a mean 8.0% body weight reduction versus 2.6% for placebo at 56 weeks, a placebo-adjusted loss of roughly 5.4 percentage points [5]. That clinical benchmark is why obesity specialists, endocrinologists, and primary-care physicians across Tennessee continue to prescribe it despite its cost.

Does TennCare (Tennessee Medicaid) Cover Liraglutide?

TennCare covers liraglutide only for type 2 diabetes management, not for chronic weight management. Patients seeking liraglutide (Victoza) for glycemic control may qualify under TennCare's preferred drug list, but those seeking Saxenda for obesity will not receive reimbursement under the standard TennCare benefit as of 2026.

This coverage gap mirrors a federal limitation. Until the Treat and Reduce Obesity Act or equivalent legislation passes Congress, Medicaid programs cannot cover anti-obesity medications as a mandatory benefit [6]. Tennessee has not added obesity pharmacotherapy as an optional state-funded benefit. The Centers for Medicare and Medicaid Services (CMS) has acknowledged the gap but has not issued a rule compelling state Medicaid plans to cover GLP-1 drugs for weight management as of the current writing [7].

Patients with TennCare MCO plans (BlueCare Tennessee, BCBST TennCare, and UnitedHealthcare Community Plan) should verify coverage directly with their plan's pharmacy benefit line, because individual MCO formularies sometimes add coverage beyond the base TennCare preferred drug list. Victoza for diabetes, specifically, appears on several TennCare MCO preferred drug lists at a preferred tier requiring prior authorization confirming a diagnosis of type 2 diabetes, a baseline HbA1c at or above 7.0%, and failure of metformin monotherapy [8].

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred add-on agents in patients with type 2 diabetes and established atherosclerotic cardiovascular disease [9]. That guideline language can strengthen a PA appeal for Victoza in TennCare.

Is Compounded Liraglutide Legal in Tennessee?

Compounded liraglutide is legal in Tennessee when prepared by a state-licensed 503A pharmacy under a valid, patient-specific prescription. It is not legal to compound liraglutide from a 503B outsourcing facility unless liraglutide appears on the FDA's drug shortage list, which it did not as of mid-2026 [10].

The distinction matters. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare copies of commercially available drugs, including liraglutide, on a patient-by-patient prescription basis without violating the act's prohibition on copying approved drugs, provided the pharmacy meets USP <795> standards and the prescriber documents a clinical reason [11]. Tennessee's Board of Pharmacy enforces these requirements locally [12].

The HealthRX clinical team uses a three-gate framework before directing a Tennessee patient toward compounded liraglutide:

1. Confirm the compounding pharmacy holds an active Tennessee Board of Pharmacy license and does not operate as an unlicensed internet pharmacy.
2. Verify the compounding formula uses liraglutide acetate (not a salt analog or a peptide with a different sequence) at the same 3 mg maximum daily dose as the FDA-approved label.
3. Review the prescriber's note for a documented clinical rationale, since bare-cost requests alone do not satisfy 503A's "valid prescription" requirement in every state interpretation.

Compounded liraglutide from a licensed Tennessee 503A pharmacy typically runs $150 per month, compared to roughly $900 per month for brand Saxenda. That price difference is real, but patients should be aware that compounded formulations do not carry the same FDA oversight for potency, sterility, or stability as brand-name products [13]. A 2023 FDA safety communication flagged that some compounded semaglutide products contained incorrect concentrations; similar risks apply to any compounded GLP-1 peptide [14].

Telehealth providers operating in Tennessee can legally prescribe liraglutide, including for compounded formulations, because Tennessee does not require an in-person visit as a prerequisite for prescribing Schedule-exempt medications [15]. The Tennessee Medical Practice Act was amended after COVID-era telemedicine expansions to allow full prescribing authority via synchronous audio-video encounters [16].

Which Insurance Plans Cover Liraglutide in Tennessee?

Coverage depends almost entirely on whether the indication is type 2 diabetes (Victoza) or obesity (Saxenda) and on whether the employer plan has explicitly included or excluded anti-obesity medications.

For type 2 diabetes, most major commercial plans operating in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, Aetna, UnitedHealthcare, and Humana, list Victoza on their formularies at Tier 3 or Tier 4, requiring a PA. The PA checklist generally asks for a documented HbA1c above 7%, a trial of metformin unless contraindicated, and a prescriber attestation of cardiovascular risk consistent with LEADER trial data [17]. The LEADER trial (N=9,340) showed liraglutide reduced the composite MACE endpoint by 13% versus placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority) in adults with type 2 diabetes and high cardiovascular risk [18].

For obesity, Saxenda coverage among Tennessee commercial plans is inconsistent. The federal Employee Retirement Income Security Act (ERISA) allows self-funded employer plans to exclude entire drug categories, and anti-obesity medications are one of the most commonly excluded categories [19]. Large employers that have added anti-obesity coverage, often after pressure from benefits consultants, may cover Saxenda with a PA requiring a BMI at or above 30 kg/m2, or a BMI at or above 27 kg/m2 with at least one weight-related comorbidity [20]. Those BMI thresholds match the FDA-approved indication for Saxenda [1].

Tennessee state employee health plans, managed through the State Group Insurance Program (SGIP), do not cover Saxenda for weight management as a standard benefit. Individual SGIP members should confirm with the Concierge Tennessee benefits portal because plan documents can change annually.

Medicare Part D plans available in Tennessee follow CMS guidance excluding most weight-loss drugs from coverage. The Inflation Reduction Act did not modify the Part D obesity drug exclusion, so Medicare enrollees in Tennessee remain ineligible for Saxenda or Victoza-for-weight-loss coverage through Part D as of 2026 [6].

How Prior Authorization Appeals Work in Tennessee

A PA denial for liraglutide in Tennessee is not necessarily the end. Tennessee law requires insurers to provide written denial reasons within 72 hours for urgent requests and 15 calendar days for standard requests [21]. Patients and prescribers have the right to request an internal appeal and, if denied, an independent external review through the Tennessee Department of Commerce and Insurance [22].

Effective appeal documentation typically includes the full prescribing label, the relevant LEADER or SCALE trial abstracts, and a letter of medical necessity from the treating physician that references ADA or Endocrine Society guidelines by name and publication year [9][23]. The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "We recommend anti-obesity pharmacotherapy as an adjunct to lifestyle therapy for adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with weight-related comorbidities when lifestyle therapy alone is insufficient" [23]. Including that direct quotation in an appeal letter gives the reviewer a guideline anchor from a recognized specialty society.

Discount Programs and the Cheapest Legal Paths in Tennessee

Several cost-reduction strategies exist for Tennessee residents who do not have insurance coverage or whose coverage tier leaves them with unaffordable copays.

Novo Nordisk Patient Assistance Program. Patients with household income at or below 400% of the federal poverty level and no insurance coverage for liraglutide may qualify for free or steeply reduced-price medication through Novo Nordisk's Patient Assistance Program [4]. Applications require income documentation and a prescriber signature. Processing can take two to four weeks.

NovoCare Savings Card. Commercially insured patients who are not on a federal program can use the NovoCare card to cap monthly cost at $25 for Saxenda [4]. The card does not apply to Medicare, Medicaid, or other government-funded plans.

GoodRx and similar discount platforms. GoodRx-type coupons at Tennessee pharmacies bring Saxenda cash price to roughly $850 to $920 per month depending on the specific chain and zip code. These coupons cannot be combined with insurance.

340B program-linked clinics. Federally Qualified Health Centers (FQHCs) in Tennessee that participate in the 340B Drug Pricing Program can dispense liraglutide at significantly reduced prices to qualifying low-income patients. Nashville's Matthew Walker Comprehensive Health Center and Memphis' Church Health are two examples of 340B-eligible sites where patients may access lower drug acquisition costs [24].

Compounded 503A route. As described above, a licensed Tennessee 503A compounding pharmacy can legally dispense patient-specific compounded liraglutide at approximately $150 per month. This route requires a valid prescription and carries the caveats about FDA oversight described in the compounding section above.

Telehealth-linked membership programs. Several telehealth platforms operating in Tennessee bundle the prescriber visit, ongoing monitoring, and pharmacy coordination into monthly memberships that include compounded liraglutide. HealthRX's Tennessee program, for example, connects patients with licensed prescribers and licensed compounding pharmacies as of 2026. Patients should verify that any telehealth platform uses a Tennessee-licensed prescriber for Tennessee residents, consistent with the Interstate Medical Licensure Compact requirements [15].

Liraglutide vs. Semaglutide: Cost Comparison for Tennessee Patients

Some Tennessee patients ask their physician whether switching to semaglutide (Ozempic for diabetes, Wegovy for obesity) offers a cost or efficacy advantage.

On efficacy, semaglutide 2.4 mg in STEP-1 (N=1,961) produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [25]. Liraglutide 3.0 mg in SCALE Obesity produced 8.0% weight loss at 56 weeks versus 2.6% for placebo [5]. The difference in weight loss between the two agents is clinically meaningful, though both are FDA-approved for chronic weight management.

On cost, brand Wegovy lists at roughly $1,349 per month as well, nearly identical to Saxenda. Compounded semaglutide was more widely available in Tennessee through 2024 and early 2025 because semaglutide appeared on the FDA shortage list during that period. Once semaglutide was removed from the shortage list in early 2025, the legal basis for 503A compounding of semaglutide narrowed substantially [10]. Liraglutide was never on the FDA shortage list during that period, meaning compounded liraglutide's legal basis rests entirely on 503A's patient-specific prescription exemption rather than the shortage pathway.

That regulatory difference means compounded liraglutide from a licensed Tennessee 503A pharmacy remained on firmer legal footing in mid-2026 than compounded semaglutide, making it a continuing option for cost-sensitive patients who have discussed risks and benefits with their prescriber [11].

Clinical Monitoring Requirements for Tennessee Liraglutide Patients

Prescribing liraglutide in Tennessee, whether via a local physician or a licensed telehealth provider, requires baseline and ongoing monitoring consistent with FDA labeling and Endocrine Society guidelines [23].

Baseline labs before initiating liraglutide should include fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, and thyroid function (TSH). The FDA label carries a black-box warning about thyroid C-cell tumors observed in rodent studies; liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1]. Prescribers should document this contraindication screen before initiating treatment.

Dose titration for Saxenda begins at 0.6 mg per day subcutaneously for one week, then increases by 0.6 mg per week to the 3 mg maintenance dose over five weeks [1]. Patients who cannot tolerate 3 mg should discontinue rather than maintain a subtherapeutic dose below 1.2 mg, because the efficacy data from SCALE Obesity were generated at the full 3 mg dose [5].

Heart rate elevations of two to three beats per minute have been documented with liraglutide in clinical trials [26]. Patients with pre-existing tachyarrhythmias should have cardiac review before starting therapy. The FDA label also notes that liraglutide is associated with acute pancreatitis; patients should be counseled to discontinue and seek care if they develop persistent severe abdominal pain [1].

Follow-up visits at four, twelve, and twenty-four weeks allow the prescriber to assess tolerability, document weight trajectory, and confirm that the patient has lost at least 4% of baseline body weight by week 16, consistent with the SCALE Obesity responder analysis that defined meaningful response [5][27].

A 2022 Cochrane systematic review of GLP-1 receptor agonists for weight management (26 trials, N=6,500+) confirmed that liraglutide 3 mg produced statistically significant weight loss versus placebo and was associated with more gastrointestinal adverse events, primarily nausea and vomiting, than placebo, with most GI events resolving within the first eight weeks [28].

Tennessee Telehealth Prescribing: What the Law Actually Requires

Tennessee licensed physicians, advanced practice registered nurses (APRNs), and physician assistants (PAs) can prescribe liraglutide via telehealth for a patient physically located in Tennessee provided the prescriber holds a valid Tennessee license or qualifies under the Interstate Medical Licensure Compact [15][16].

Tennessee's APRN law allows full prescriptive authority for APRNs with a collaborative agreement with a supervising physician in most outpatient settings. Physician assistants require a supervising physician and a written practice protocol. Both designations can prescribe liraglutide without restriction on the prescribing modality (in-person vs. telehealth) as long as the clinical encounter meets standard-of-care documentation requirements [16].

Prescriptions for liraglutide written via telehealth in Tennessee must include the patient's name, date of birth, prescriber's name and DEA number (if applicable, though liraglutide is non-scheduled), drug name, strength, quantity, and directions for use. Electronic prescribing to a Tennessee-licensed pharmacy, including a 503A compounding pharmacy, fully satisfies these requirements [12].

The Tennessee Board of Medical Examiners has not issued specific restrictions on GLP-1 prescribing via telehealth beyond the general standard-of-care requirements applicable to all telehealth encounters. The prescriber must conduct a sufficient evaluation to establish a diagnosis and confirm absence of contraindications [16].